Popular terms

[SEARCH]

Autoimmune Diseases topics
Immune Diseases
Autoimmune Disease
Autoimmune Diseases
Immune Disease
Autoimmune
Rheumatoid Arthritis
Antibodies
Proliferative
Nucleotide
Antagonist
Infectious Diseases
Inflammatory Disease
Infectious Disease
Infectious
Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Diseases patents



      
           
This page is updated frequently with new Autoimmune Diseases-related patent applications. Subscribe to the Autoimmune Diseases RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune Diseases RSS RSS



Date/App# patent app List of recent Autoimmune Diseases-related patents
08/20/15
20150231281 
 Inflammation imaging and therapy patent thumbnailInflammation imaging and therapy
An imaging agent comprising a conjugate of an oligosaccharide moiety with an imaging moiety. The oligosaccharide is lewis a or lewis b or a mimetic thereof, or a pharmaceutically acceptable salt or pegylated form of lewis a or lewis b or its mimetics.
Isis Innovation Limited


08/13/15
20150225398 
 Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders patent thumbnailNovel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

08/13/15
20150224199 
 Pharmaceutical compositions for the treatment of inflammatory disorders patent thumbnailPharmaceutical compositions for the treatment of inflammatory disorders
Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

08/13/15
20150224146 
 Cell populations having immunoregulatory activity,  isolation and uses patent thumbnailCell populations having immunoregulatory activity, isolation and uses
The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (ifn-γ) by expressing indolamine-2,3-dioxygenase (ido) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.. .
Consejo Superior De Investigaciones Cientificas


08/13/15
20150224141 
 Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases patent thumbnailMethods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases
Methods for enhancing the suppressive function of myeloid derived suppressor cells (mdscs) for the treatment of autoimmune diseases using small compounds are disclosed. In certain aspects, the small compounds are glatiramer acetate and mitogen activated protein (map) kinase inhibitors.
Icahn School Of Medicine At Mount Sinai


08/06/15
20150218260 
 Interleukin-2 fusion proteins and uses thereof patent thumbnailInterleukin-2 fusion proteins and uses thereof
The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (il-2). More particularly, the invention concerns fusion proteins of immunoglobulins and mutant il-2 that exhibit improved properties for use as therapeutic agents, e.g.
Hoffman-la Roche Inc.


08/06/15
20150218239 
 Fcrn antagonists and methods of use patent thumbnailFcrn antagonists and methods of use
Provided are novel fcrn antagonist compositions comprising a variant fc region that binds specifically to fcrn with increased affinity and reduced ph dependence relative to the native fc region. Also provided are fcrn antagonists with enhanced cd16 binding affinity.
The Board Of Regents Of The University Of Texas System


08/06/15
20150216971 
 Methods for treating gi syndrome and graft versus host disease patent thumbnailMethods for treating gi syndrome and graft versus host disease
It has been discovered that administering therapeutically effective amounts of an antibiotic that kills gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic t lymphocyte (ctl)-induced killing and/or by damage to endothelial microvasculature, including radiation gi syndrome, cgvhd disease, inflammatory diseases and autoimmune diseases.. .
Sloan Kettering Institute For Cancer Research


07/30/15
20150210703 
 Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases patent thumbnailImidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof. The formula i compounds inhibit tyrosine kinase activity of jak3, thereby making them useful for the treatment of inflammatory and autoimmune diseases..
Bristol-myers Squibb Company


07/23/15
20150203847 
 Chemical modifications of monomers and oligonucleotides with cycloaddition patent thumbnailChemical modifications of monomers and oligonucleotides with cycloaddition
In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..

07/23/15
20150203560 

Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases


The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides novel genetically engineered fusion molecules comprising an interferon (ifn) molecule attached to an antibody (ab) which targets an antigen which is differentially expressed or up-regulated on activated t cells as compared to resting t cells, wherein the fusion molecule when contacted to an activated t cell results in induced apoptosis and programmed cell death or impairment of functions of said activated t cell..
Immungene Inc.


07/23/15
20150203455 

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


Wherein cy, r1, l1, r3, r4, r5, la, and ra are as defined herein. Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons..

07/23/15
20150202318 

Aberrant cell-restricted immunoglobulins provided with a toxic moiety


Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.


07/23/15
20150202285 

Compositions and methods for modulating immune responses


This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the nf-κb signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases..
The University Of Queensland


07/16/15
20150196511 

Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease


The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of il-17 and tnf-a, and promoting or increasing the activity of ifnr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease..
Catholic University Industry Academic Cooperation Foundation


07/09/15
20150191699 

Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof


The disclosure provided herein relates generally to mesenchymal-like stem cells “hes-t-misc” or “t-msc” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hes-t-msc or t-msc, t-msc derived cells and cell lineages “t-msc-dl” are also described.
Imstem Biotechnology, Inc.


07/09/15
20150191464 

Heteroaryl substituted nicotinamide compounds


Or salts thereof, wherein: het is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1h-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with ra and rb; and r1 and r2 are define herein. Also disclosed are methods of using such compounds as modulators of irak4, and pharmaceutical compositions comprising such compounds.

07/09/15
20150191417 

Anti-proliferative compounds and uses thereof


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject.
The General Hospital Corporation D/b/a Massachusetts General Hospital


07/02/15
20150183775 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


07/02/15
20150182539 

Pregnancy hormone combination for treatment of autoimmune diseases


The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune disorders, such as multiple sclerosis.. .
The Regents Of The University Of California


06/25/15
20150175979 

Ptprs and proteoglycans in autoimmune disease


Provided herein, inter alia, are ptprs de-clustering agents and compositions and kits comprising the agents. Provided are methods of modulating extracellular matrix or decreasing fibroblast activity in a subject.
La Jolla Institute For Allergy And Immunology


06/25/15
20150174178 

Method and system for prevention and treatment of allergic and inflammatory diseases


A method and system for exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..

06/18/15
20150166658 

Bcr-complex-specific antibodies and methods of using same


This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.


06/18/15
20150165006 

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen


The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising an allergenic antigen or an autoimmune self-antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein.
Cure Gmbh


06/18/15
20150164902 

Concentrated methotrexate solutions


Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml..
Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh


06/11/15
20150158912 

Treatment of il-17 mediated disease by blocking sefir-sefir interactions


A method of treating an il-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the sefir domain of il-17r to the sefir domain of act1. In particular, it has been determined that the αc helix region of the sefir domain of both il-17r and act1 plays an important role in the association of il-17r and act1.
The Cleveland Clinic Foundation


06/11/15
20150158871 

Crystalline forms of a bruton's tyrosine kinase inhibitor


Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics, Inc.


06/11/15
20150158865 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are reversible and irreversible inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Pharmacyclics, Inc.


06/04/15
20150152097 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


06/04/15
20150150951 

Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity


The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.

06/04/15
20150150912 

Ceacam1 mediated protective immunity


The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the supression of immune responses in a targeted fashion, by increasing the functional concentration of the ceacam1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue..

05/28/15
20150148361 

Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.. .
Janssen Pharmaceutica Nv


05/21/15
20150141523 

Compounds for use in the treatment of autoimmune inflammatory disease


And salts thereof is useful in the prophylaxis or treatment of inflammatory bowel disease or other inflammatory autoimmune diseases with similar aetiology involving t-cell proliferation or or function.. .

05/21/15
20150141397 

Substituted anilines as ccr(4) antagonists


Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.


05/21/15
20150141328 

Stimulation of human meibomian gland function


Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a pld-inducing compound, such as the cationic amphiphilic drugs (e.g. Azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, igf-1 or an igf-1 analogue (e.g.
The Schepens Eye Research Institute


05/21/15
20150140085 

Formulations comprising ibrutinib


Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases.. .
Principia Biopharma Inc.


05/14/15
20150132788 

Establishing the viability of biological samples


The invention relates to a method, a use and a kit for establishing the viability (ability to live) of biological samples using ageladine a. The invention is advantageously suitable for establishing the viability of biological samples which can otherwise be dyed in an intra-cellular manner by fluorescence dyes other than ageladine a not at all or only with difficulty.

05/14/15
20150132369 

Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof


A liposomal formulation for targeting immunotherapy, with synergistic effect in the case of encapsulating an immunosuppressive drug, such as cyclosporine a, and the method of preparing the same. The reduced toxicity and significant reduction of delayed-type hypersensitivity dth) due to extremely reduced dosage, potential therapeutic value in control of chronic transplant rejection, allergies and certain autoimmune diseases, and increased efficacy are some of numerous and significant benefits of the present invention..

05/14/15
20150132326 

Immunosuppressive blood cells and methods of producing the same


The present invention refers to a method of producing immunosuppressive blood cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.. .

05/14/15
20150132312 

Systems and methods for extracorporeal blood modification


The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject.

05/07/15
20150125880 

Methods for induction of antigen-specific regulatory t cells


The present invention relates to methods to elicit immature antigen-presenting cells loaded with apoptotic cells or apoptotic bodies. The present invention also relates to methods of obtaining antigen-specific regulatory t cells in vitro or in vivo.
Katholieke Universiteit Leuven


05/07/15
20150125536 

Methods and compositions for sustained immunotherapy


This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of tr1 cells and/or breg cells in an antigen-specific manner and treating autoimmune diseases and disorders in a subject in need thereof.. .
Uti Limited Partnership


05/07/15
20150125460 

Anti-bcma antibodies


This invention provides antibodies that recognize the b cell maturation antigen (bcma) and that bind naïve b cells, plasma cells, and/or memory b cells. The invention further provides methods for depleting naïve b cells, plasma cells, and memory b cells, and for treating b cell-related disorders, including lymphomas and autoimmune diseases..
Biogen Idec Ma Inc.


05/07/15
20150125390 

18f-labelled folate/antifolate analogues


The present invention is directed towards new 18f-folate/antifolate analogue radiopharmaceuticals, wherein the phenyl group within folate structures has been replaced by an 18f-heterocycle, their precursors, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.. .
Merck & Cie


04/30/15
20150118318 

Methods of treating inflammatory and autoimmune diseases and disorders


Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder.
Yale University


04/30/15
20150118264 

Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen


The present invention is directed to a pharmaceutical composition including (e.g. For use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
Curevac Gmbh


04/30/15
20150118259 

28 kda gst proteins from schistosoma for the use thereof in the treatment of inflammatory autoimmune diseases generating a th1 and/or th17 response


The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kda glutathione s-transferase protein from a schistosome selected from schistosoma haematobium, schistosoma mansoni, schistosoma bovis represented respectively by the sequences seq id no: 1, seq id no: 2 and seq id no: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type th1 and/or th17.. .
Centre Hospitalier Regional Universitaire De Lille


04/30/15
20150118183 

Negatively charged nucleic acid comprising complexes for immunostimulation


The present invention is directed to a pharmaceutical composition including (e.g., for use as an adjuvant) a (negatively charged) nucleic acid comprising complex comprising as a carrier cationic or polycationic compounds (e.g. Peptides, proteins or polymers) and as a cargo at least one nucleic acid (molecule) and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
Curevac Gmbh


04/23/15
20150111873 

Pharmaceutically active pyrazolo-triazine derivatives


Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase..
Lead Discovery Center Gmbh


04/23/15
20150111872 

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.. .

04/23/15
20150111835 

Modified peptides and their use for treating autoimmune diseases


The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence ihmvyskrsgkprgyafiey, comprising one or more post-translational modifications.. .
Centre National De La Rechereche Scientifique


04/23/15
20150110805 

Therapeutic strategy for treating autoimmune and degenerative diseases


Numerous diseases have been linked to the production of effector cells. The present invention relates to the realization that effector cells are cycling in these diseases.
Immunaid Pty Ltd.


04/16/15
20150104866 

Ip-10 antibodies and their uses


The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to ip-10 with high affinity, inhibit the binding of ip-10 to its receptor, inhibit ip-10-induced calcium flux and inhibit ip-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Medarex, L.l.c.


04/09/15
20150099770 

Carboxylic acid compounds


The present disclosure concerns at least one entity chosen from compounds of formula (i) and pharmaceutically acceptable salts thereof: (i) wherein the variable groups x, r1, r2, r3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer..
Astrazeneca Aktiebolag


04/09/15
20150099001 

Nanocell drug delivery system


Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
Massachusetts Institute Of Technology


04/09/15
20150098955 

Cd40l-specific tn3-derived scaffolds and methods of use thereof


The present invention provides tenascin-3 fniii domain-based scaffolds that specifically bind to cd40l. The invention further provides engineered variants with increased affinity for the target.
Medlmmune, Llc


04/02/15
20150094319 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.


04/02/15
20150093799 

Histidyl-trna synthetases for treating autoimmune and inflammatory diseases


The present invention relates generally to compositions and methods comprising histidyl-trna synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to jo-1 antibodies.. .
Atyr Pharma, Inc.


03/26/15
20150087643 

Substituted fused pyrimidine compounds


The present invention discloses substituted fused pyrimidine compounds of formula (i), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (ar) activity; the compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.. .
Advinus Therapeutics Private Limited


03/26/15
20150087620 

Amine compound and use thereof for medical purposes


Wherein each symbol is as described in the description, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (gvh) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.. .

03/26/15
20150087529 

Sequencing analysis of circulating dna to detect and monitor autoimmune diseases


Systems, methods, and apparatuses are provided for diagnosing auto-immune diseases such as systemic lupus erythematosus (sle) based on the sizes, methylation levels, and/or genomic characteristics of circulating dna molecules. Patients provide blood or other tissue samples containing cell-free nucleic molecules for analysis.
The Chinese University Of Hong Kong


03/19/15
20150080391 

Novel compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders


The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and their use in the prophylaxis and/or treatment of inflammatory conditions, type 2 diabetes, neurological and/or neurodegenerative diseases, autoimmune diseases, proliferative diseases (in particular metastatic diseases, and/or cancer), abnormal angiogenesis associated diseases, degradation of cartilage, and/or disruption of cartilage homeostasis, in particular in the prophylaxis and/or treatment of cancer. The present invention also discloses methods of treatment using the same compounds, for the prophylaxis and/or treatment of said diseases by administering the compound of the invention..

03/19/15
20150080369 

Novel compounds


The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited


03/19/15
20150080356 

Method for improving therapy for autoimmune diseases such as rheumatoid arthritis


In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. A pharmaceutical composition containing this combination is useful for the treatment of autoimmune diseases.
Toyama Chemical Co., Ltd.


03/12/15
20150072986 

Urea derivatives and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.


03/12/15
20150072980 

Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis


The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc


03/12/15
20150072978 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


03/05/15
20150065507 

Novel compounds


The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited


02/26/15
20150057297 

Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions


The present invention provides halofuginol, and derivatives and salts thereof, including diasteromerically enriched compositions thereof. The invention also provides pharmaceutical and cosmetic compositions thereof as well as methods for using halofuginol and derivatives thereof in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, malaria, ischemic damage, transplant rejection, neurodegenerative diseases, t-cell neoplasms, and cosmetic conditions..
The General Hospital Corporation D/b/a Massachusetts General Hospital


02/26/15
20150056198 

Aberrant cell-restricted immunoglobulins provided with a toxic moiety


Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.


02/26/15
20150056185 

Immunoglobulin constant region fc receptor binding agents


Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function.
University Of Maryland, Baltimore


02/19/15
20150051242 

Rafamycin analogs and methods for making same


A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mtor inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal.
Zhejiang Zylox Medical Device Co., Ltd.


02/19/15
20150051196 

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..

02/19/15
20150051178 

Estriol therapy for autoimmune and neurodegenerative diseases and disorders


The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period..
The Regents Of The University Of California


02/19/15
20150050210 

Pharmaceutical formulation comprising bendamustine


The present invention is related to the field of pharmaceutical compositions for the treatment of various disease states, particularly neoplastic diseases and autoimmune diseases. It especially relates to the oral application of bendamustine and its derivatives.
Salmon Pharma Gmbh


02/12/15
20150045361 

Heterocyclic compounds and their uses


Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.


02/12/15
20150045324 

Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity


The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.. .
Hanmi Science Co., Ltd


02/12/15
20150044244 

Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases


The present invention relates to treating and preventing symptoms of an allergy, asthma, an autoimmune disease, and transplant rejection using a combination vaccine containing a vaccine facilitator comprising a na/k pump inhibitor, an antigen and a dna encoding the antigen.. .
Beijing Advanccine Biotechnology Co. Ltd.


02/12/15
20150044164 

Methods of treating autoimmune diseases


Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent tgf-β and/or another agent that promotes expansion of regulatory t cells.
Genzyme Corporation


02/12/15
20150044134 

Compositions, methods and kits for treatment of cancer and autoimmune diseases


The present invention is directed to fusion proteins having an il-21 cytokine portion and an anti-cd20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the il-21-anti-cd20 fusion proteins.
University Of Miami


02/05/15
20150038545 

Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof


As well as to the procedure for their preparation, pharmaceutical compositions comprising the same and the use thereof for the treatment and/or prevention of a condition mediated by histone deacetylase such as cancer, hematological malignancies, autoimmune diseases, inflammatory diseases, diseases of the central nervous system (cns) such as neurodegenerative diseases and psychiatric disorders, cardiovascular diseases, endocrine and metabolic disorders, by inhibiting histone deacetylases and the therapeutic use of biological processes related to the mentioned inhibition.. .

02/05/15
20150038538 

Thiadiazolidinediones as gsk-3 inhibitors


The present invention relates to new thiadiazolidinediones of formula (i), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (gsk-3) is involved, particularly neurodegenerative diseases, inflammatory and autoimmune diseases and cardiovascular disorders. Additionally, there is provided a process for preparing such compounds, as well as pharmaceutical compositions comprising them..
Asd Therapeutics Partners Llc


02/05/15
20150038480 

Compounds that modulate autoimmunity and methods of using the same


The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of mhc class ii molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same..
The Regents Of The University Of Colorado, A Body Corporate


02/05/15
20150037886 

Treatment drug for autoimmune diseases and allergic diseases


The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-embigin antibody, particularly an anti-embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving th17 cell, and a cytotoxic agent to th17 cell. In addition, an agent for detection of th17 cell, which contains an anti-embigin antibody, a convenient detection method of th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a th17 cell selective manner, which uses an anti-embigin antibody, and a drug delivery system to th17 cell are provided..
Sumitomo Dainippon Pharma Co., Ltd.


01/29/15
20150031706 

Novel compound useful for the treatment of degenerative and inflammatory diseases


A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..

01/29/15
20150031671 

Novel compound useful for the treatment of degenerative and inflammatory diseases


This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6.. .

01/22/15
20150023976 

Antibody polypeptides that antagonize cd40l


Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Domantis Limited


01/15/15
20150018336 

Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.


01/15/15
20150018329 

Pharmaceutically active pyrazolo-triazine derivatives


The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase..
Lead Discovery Center Gmbh


01/15/15
20150017164 

Combination of blys and/or april inhibition and immunosuppressants for treatment of autoimmune disease


The invention relates to novel combination therapies involving blys or blys/april inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the blys and/or april antagonist is a fc-fusion protein which can be a taci-fc-fusion protein comprising the extracellular domain of taci or a functional fragment thereof, a baff-r-fc-fusion protein comprising the extracellular domain of baff-r or a functional fragment thereof, or a bcma-fc-fusion protein comprising the extracellular domain of bcma or a functional fragment thereof.
Ares Trading S.a.


01/15/15
20150017132 

Mesenchymal stem cells and uses therefor


Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
Mesoblast International Sárl


01/08/15
20150011767 

Use of koumine and its homologues in preparation of medicament for treatment of autoimmune diseases of involved bones and joints


The present invention discloses an application of koumine and homologue thereof in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like, in particular an application of gelsemium alkaloid monomer koumine and homologue thereof or pharmaceutically acceptable salt thereof as active ingredient in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like. The result of pharmacology experiment shows that koumine can decrease the generation of organism antibody against autoimmune diseases involving bones and joints in a dose dependent manner, improve symptoms of swelling and hyperalgesia, reduce arthritis index, reverse joint pathological changes, and has no serious shortage of commonly used clinical drugs; thus koumine has an effect against autoimmune diseases involving bones and joints including rheumatoid arthritis, ankylosing spondylitis etc.
Fujian Medical University




Popular terms: [SEARCH]

Autoimmune Diseases topics: Immune Diseases, Autoimmune Disease, Autoimmune Diseases, Immune Disease, Autoimmune, Rheumatoid Arthritis, Antibodies, Proliferative, Nucleotide, Antagonist, Infectious Diseases, Inflammatory Disease, Infectious Disease, Infectious, Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.2967

5554

4 - 0 - 101